NEW YORK (TheStreet) -- Metlife (MET) shares are down -0.6% to $54.94 on Friday after the Financial Stability Oversight Council proposed to designate the insurer as "systemically important", a designation that opens Metlife up to stricter regulatory rules.
The appointment carries with it stricter capital requirements and increased oversight from the Federal Reserve comparable to the oversight big banks like JPMorgan (JPM) and Citigroup (C) now experience.
Must Read: Warren Buffett's 25 Favorite Stocks
Metlife has come out in opposition of the classification, saying that it "strongly disagrees" with the designation which has already been given to fellow insurers Prudential Financial (PRU) and AIG (AIG) .
TheDeal has in depth coverage of the regulatory process here.
TheStreet Ratings team rates METLIFE INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate METLIFE INC (MET) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow."